Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · see citing works

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · see citing works

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · see citing works

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802 · see citing works

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · see citing works

In-gel digestion for mass spectrometric characterization of proteins and proteomes

Shevchenko, A., Tomas, H., Havli, J., Olsen, J. V., & Mann, M. (2006) · Nature Protocols · doi:10.1038/nprot.2006.468 · Cited by 4,867 · see citing works

Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips

Rappsilber, J., Mann, M., & Ishihama, Y. (2007) · Nature Protocols · doi:10.1038/nprot.2007.261 · Cited by 4,641 · see citing works

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286 · see citing works

Tumor-Associated Macrophages: From Mechanisms to Therapy

Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089 · see citing works

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

Powles, T. B., Eder, J. P., Fine, G. D., Braiteh, F. S., Loriot, Y., Cruz, C., Joaquim Bellmunt, B., Burris, H. A., Petrylak, D. P., Teng, S.-L. M., et al. (2014) · Nature · doi:10.1038/nature13904 · Cited by 2,383 · see citing works

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.016 · Cited by 2,127 · see citing works

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

Curran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915174107 · Cited by 1,874 · see citing works

Mechanisms of Foxp3+ T Regulatory Cell-Mediated Suppression

Shevach, E. M. (2009) · Immunity · doi:10.1016/j.immuni.2009.04.010 · Cited by 1,754 · see citing works

Parallel reaction monitoring for high resolution and high mass accuracy quantitative, targeted proteomics

Peterson, A. C., Russell, J. D., Bailey, D. J., Westphall, M. S., & Coon, J. J. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.o112.020131 · Cited by 1,288 · see citing works

A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer

Kershaw, M. H., Westwood, J. A., Parker, L. L., Wang, G., Eshhar, Z., Mavroukakis, S. A., White, D. E., Wunderlich, J. R., Canevari, S., Rogers-Freezer, L. J., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1183 · Cited by 1,254 · see citing works

Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition

Cherkassky, L., Morello, A., Villena‐Vargas, J., Feng, Y., Dimitrov, D. S., Jones, D. R., Sadelain, M., & Adusumilli, P. S. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83092 · Cited by 1,075 · see citing works

IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer

Abiko, K., Matsumura, N., Hamanishi, J., Horikawa, N., Murakami, R., Yamaguchi, K., Yoshioka, Y., Baba, T., Konishi, I., & Mandai, M. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.101 · Cited by 725 · see citing works

Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells

John, L. B., Devaud, C., Duong, C. P. M., Yong, C. S. M., Beavis, P. A., Haynes, N. M., Chow, M. T., Smyth, M. J., Kershaw, M. H., & Darcy, P. K. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0458 · Cited by 699 · see citing works

Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning

Pegram, H. J., Lee, J., Hayman, E. G., Imperato, G. H., Tedder, T. F., Sadelain, M., & Brentjens, R. J. (2012) · Blood · doi:10.1182/blood-2011-12-400044 · Cited by 677 · see citing works

Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance

Sabatos, C. A., Chakravarti, S., Cha, E., Schubart, A., Fueyo, A. S., Zheng, X. X., Coyle, A. J., Strom, T. B., Freeman, G. J., & Kuchroo, V. K. (2003) · Nature Immunology · doi:10.1038/ni988 · Cited by 629 · see citing works

Driving CAR T-cells forward

Jackson, H. J., Rafiq, S., & Brentjens, R. J. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.36 · Cited by 613 · see citing works

LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems.

Grosso, J., Kelleher, C. C., Harris, T., Maris, C. H., Hipkiss, E. L., Marzo, A. D. D., Anders, R., Netto, G., Getnet, D., Bruno, T., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31184 · Cited by 531 · see citing works

A high M1/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients

Zhang, M., He, Y., Sun, X., Li, Q. Y., Wang, W., Zhao, A., & Di, W. J. (2014) · Journal of Ovarian Research · doi:10.1186/1757-2215-7-19 · Cited by 530 · see citing works

A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors

Liu, X., Ranganathan, R., Jiang, S., Fang, C., Sun, J., Kim, S., Newick, K., Lo, A., June, C. H., Zhao, Y., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2524 · Cited by 525 · see citing works

IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo

Koneru, M., Purdon, T. J., Spriggs, D. R., Koneru, S., & Brentjens, R. J. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.994446 · Cited by 419 · see citing works

Single‐institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting

Ku, G. Y., Yuan, J. D., Page, D. B., Schroeder, S. E. A., Panageas, K. S., Carvajal, R. D., Chapman, P. B., Schwartz, G. K., Allison, J. P., & Wolchok, J. D. (2010) · Cancer · doi:10.1002/cncr.24951 · Cited by 418 · see citing works

Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment

Yeku, O., Purdon, T. J., Koneru, M., Spriggs, D. R., & Brentjens, R. J. (2017) · Scientific Reports · doi:10.1038/s41598-017-10940-8 · Cited by 411 · see citing works

Improved Survival with T Cell Clonotype Stability After Anti–CTLA-4 Treatment in Cancer Patients

Cha, E., Klinger, M., Hou, Y., Cummings, C., Ribas, A., Faham, M., & Fong, L. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008211 · Cited by 383 · see citing works

Lymphocyte Activation Gene-3 (CD223) Regulates the Size of the Expanding T Cell Population Following Antigen Activation In Vivo

Workman, C. J., Cauley, L. S., Kim, I.-J., Blackman, M. A., Woodland, D. L., & Vignali, D. A. A. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.9.5450 · Cited by 351 · see citing works

Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System

Avanzi, M. P., Yeku, O., Li, X., Wijewarnasuriya, D., van Leeuwen, D. G., Cheung, K., Park, H., Purdon, T. J., Daniyan, A. F., Spitzer, M. H., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.04.051 · Cited by 345 · see citing works

Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model

Suarez, E. R., Chang, D.-K., Sun, J., Sui, J., Freeman, G. J., Signoretti, S., Zhu, Q. K., & Marasco, W. A. (2016) · Oncotarget · doi:10.18632/oncotarget.9114 · Cited by 340 · see citing works

Gene Signature in Melanoma Associated With Clinical Activity: A Potential Clue to Unlock Cancer Immunotherapy

Gajewski, T. F., Louahed, J., & Brichard, V. G. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181eacbd8 · Cited by 250 · see citing works

Immune checkpoint blockade in hematologic malignancies

Armand, P. A. (2015) · Blood · doi:10.1182/blood-2015-02-567453 · Cited by 238 · see citing works

Enhancing Antitumor Efficacy of Chimeric Antigen Receptor T Cells Through Constitutive CD40L Expression

Curran, K. J., Seinstra, B. A., Nikhamin, Y., Yeh, R., Usachenko, Y., van Leeuwen, D. G., Purdon, T. J., Pegram, H. J., & Brentjens, R. J. (2015) · Molecular Therapy · doi:10.1038/mt.2015.4 · Cited by 217 · see citing works

Multiplexed peptide analysis using data-independent acquisition and Skyline

Egertson, J. D., MacLean, B., Johnson, R. S., Xuan, Y., & MacCoss, M. J. (2015) · Nature Protocols · doi:10.1038/nprot.2015.055 · Cited by 211 · see citing works

Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer.

Shaw, A. R., Porter, C. E., Watanabe, N., Tanoue, K., Sikora, A., Gottschalk, S., Brenner, M., & Suzuki, M. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.09.010 · Cited by 202 · see citing works

Tumor PD-L1 co-stimulates primary human CD8+ cytotoxic T cells modified to express a PD1:CD28 chimeric receptor

Prosser, M. E., Brown, C. E., Shami, A. F., Forman, S. J., & Jensen, M. C. (2012) · Molecular Immunology · doi:10.1016/j.molimm.2012.03.023 · Cited by 186 · see citing works

Successful Eradication of Established Peritoneal Ovarian Tumors in SCID-Beige Mice following Adoptive Transfer of T Cells Genetically Targeted to the MUC16 Antigen

Chekmasova, A. A., Rao, T. D., Nikhamin, Y., Park, K. J., Levine, D. A., Spriggs, D. R., & Brentjens, R. J. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0192 · Cited by 170 · see citing works

IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia

Pegram, H. J., Purdon, T. J., van Leeuwen, D. G., Curran, K. J., Giralt, S. A., Barker, J. N., & Brentjens, R. J. (2014) · Leukemia · doi:10.1038/leu.2014.215 · Cited by 155 · see citing works

Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen

Rafiq, S., Purdon, T. J., Daniyan, A. F., Koneru, M., Dao, T., Liu, C., Scheinberg, D. A., & Brentjens, R. J. (2016) · Leukemia · doi:10.1038/leu.2016.373 · Cited by 154 · see citing works

Sensitive in vivo imaging of T cells using a membrane-bound Gaussia princeps luciferase

Santos, E. B., Yeh, R., Lee, J., Nikhamin, Y., Punzalan, B. J., Punzalan, B., Perle, K. L., Larson, S. M., Sadelain, M., & Brentjens, R. J. (2009) · Nature Medicine · doi:10.1038/nm.1930 · Cited by 132 · see citing works

Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer

Knutson, K. L., Maurer, M. J., Preston, C. C., Moysich, K. B., Goergen, K. M., Hawthorne, K. M., Cunningham, J. M., Odunsi, K. O., Hartmann, L. C., Kalli, K. R., et al. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1753-x · Cited by 62 · see citing works

Suppression of T cell responses in the tumor microenvironment

Frey, A. B. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.08.096 · Cited by 60 · see citing works

Measurement of Fractional Synthetic Rates of Multiple Protein Analytes by Triple Quadrupole Mass Spectrometry

Lee, A. Y. H., Yates, N. A., Ichetovkin, M., Deyanova, E. G., Southwick, K., Fisher, T. S., Wang, W., Loderstedt, J., Walker, N. D., Zhou, H., et al. (2012) · Clinical Chemistry · doi:10.1373/clinchem.2011.172429 · Cited by 27 · see citing works

FoxP3+ regulatory T cells in peripheral blood of patients with epithelial ovarian cancer.

Erfani, N., Shahraki, M. H., Rezaeifard, S., Haghshenas, M., Rasouli, M., & Dehaghani, A. S. (2014) · PubMed · doi:10.22034/iji.2014.16771 · Cited by 22 · see citing works

A guide to cancer immunotherapy: from T cell basic science to clinical practice

Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0306-5 · Cited by 4,154 · see citing works

Engineering strategies to overcome the current roadblocks in CAR T cell therapy

Rafiq, S., Hackett, C. S., & Brentjens, R. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0297-y · Cited by 1,477 · see citing works

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445 · see citing works

‘Off-the-shelf’ allogeneic CAR T cells: development and challenges

Depil, S., Duchateau, P. N., Grupp, S. A., Mufti, G. J., & Poirot, L. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0051-2 · Cited by 1,236 · see citing works

Clinical implications of T cell exhaustion for cancer immunotherapy

Chow, A., Perica, K., Klebanoff, C. A., & Wolchok, J. D. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00689-z · Cited by 1,044 · see citing works

CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment

Martinez, M. C., & Moon, E. K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00128 · Cited by 855 · see citing works

Recent advances and discoveries in the mechanisms and functions of CAR T cells

Larson, R. C., & Maus, M. V. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00323-z · Cited by 852 · see citing works

CAR-NK cells: A promising cellular immunotherapy for cancer

Xie, G., Dong, H., Liang, Y., Ham, J. D., Rizwan, R., & Chen, J. (2020) · eBioMedicine · doi:10.1016/j.ebiom.2020.102975 · Cited by 800 · see citing works

Cancer immunotherapy: Pros, cons and beyond

Tan, S., Li, D., & Zhu, X. M. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.109821 · Cited by 694 · see citing works

CAR immune cells: design principles, resistance and the next generation

Labanieh, L., & Mackall, C. (2023) · Nature · doi:10.1038/s41586-023-05707-3 · Cited by 606 · see citing works

Engineering CAR-T Cells for Next-Generation Cancer Therapy

Hong, M., Clubb, J. D., & Chen, Y. Y. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.07.005 · Cited by 644 · see citing works

CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances

Makni‐Maalej, K., Merhi, M., Inchakalody, V. P., Mestiri, S., Alam, M. A., Maccalli, C., Cherif, H., Shahab Uddin, M. S., Steinhoff, M. S., Marincola, F. M., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01723-z · Cited by 638 · see citing works

Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors

Grosser, R., Cherkassky, L., Chintala, N., & Adusumilli, P. S. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.09.006 · Cited by 603 · see citing works

CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity

Choi, B. D., Yu, X., Castaño, A. P., Bouffard, A. A., Schmidts, A., Larson, R. C., Bailey, S. R., Boroughs, A. C., Frigault, M. J., Leick, M. B., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0192-1 · Cited by 575 · see citing works

Advances in cancer immunotherapy 2019 – latest trends

Krüger, S., Ilmer, M., Kobold, S., Cadilha, B. L., Endres, S., Ormanns, S., Schuebbe, G., Renz, B. W., D’Haese, J. G., Schlößer, H., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1266-0 · Cited by 560 · see citing works

Navigating CAR-T cells through the solid-tumour microenvironment

Hou, A. J., Chen, L. C., & Chen, Y. Y. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00189-2 · Cited by 556 · see citing works

Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells

Benmebarek, M.-R., Karches, C. H., Cadilha, B. L., Lesch, S., Endres, S., & Kobold, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061283 · Cited by 535 · see citing works

CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma

Rejeski, K., Perez, A. P., Sesques, P., Hoster, E., Berger, C., Jentzsch, L., Mougiakakos, D., Frölich, L., Ackermann, J., Bücklein, V., et al. (2021) · Blood · doi:10.1182/blood.2020010543 · Cited by 490 · see citing works

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Wu, M., Huang, Q., Xie, Y., Wu, X., Ma, H., Zhang, Y., & Xia, Y. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01242-2 · Cited by 471 · see citing works

The Emerging Landscape of Immune Cell Therapies

Weber, E. W., Maus, M. V., & Mackall, C. L. (2020) · Cell · doi:10.1016/j.cell.2020.03.001 · Cited by 445 · see citing works

CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges

Zhang, X., Zhu, L., Zhang, H., Chen, S., & Xiao, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.927153 · Cited by 416 · see citing works

Enhancing anti-tumour efficacy with immunotherapy combinations

Meric‐Bernstam, F., Larkin, J., Tabernero, J. M., & Bonini, C. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32598-8 · Cited by 412 · see citing works

Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion

Gumber, D., & Wang, L. D. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103941 · Cited by 409 · see citing works

Recent advances in CAR-T cell engineering

Huang, R., Li, X., He, Y., Zhu, W., Gao, L., Liu, Y. Z., Gao, L., Qin, W., Zhong, J. F., Zhang, C., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00910-5 · Cited by 408 · see citing works

CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors

Jin, L., Tao, H., Karachi, A., Long, Y., Hou, A. Y., Meng, N., Dyson, K. A., Grippin, A., Deleyrolle, L. P., Zhang, W., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11869-4 · Cited by 388 · see citing works

CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?

Wagner, J., Wickman, E., DeRenzo, C. C., & Gottschalk, S. M. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.015 · Cited by 383 · see citing works

Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL

Zhang, J., Hu, Y., Yang, J., Li, W., Zhang, M., Wang, Q., Zhang, L., Wei, G., Tian, Y., Zhao, K., et al. (2022) · Nature · doi:10.1038/s41586-022-05140-y · Cited by 380 · see citing works

Principles and therapeutic applications of adaptive immunity

Chi, H., Pepper, M., & Thomas, P. G. (2024) · Cell · doi:10.1016/j.cell.2024.03.037 · Cited by 359 · see citing works

T Cell Dysfunction in Cancer Immunity and Immunotherapy

Xia, A., Zhang, Y., Jiang, X., Yin, T., & Lu, X. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01719 · Cited by 338 · see citing works

CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape

Rodríguez-García, A., Palazón, A., Noguera-Ortega, E., Powell, D. J., & Guedan, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01109 · Cited by 317 · see citing works

CAR T cells: Continuation in a revolution of immunotherapy

Singh, A. K., & McGuirk, J. P. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30823-x · Cited by 303 · see citing works

IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases

Zhao, Y., Chen, J., Andreatta, M., Feng, B., Xie, Y., Wenes, M., Wang, Y., Gao, M., Hu, X., Romero, P. J., et al. (2024) · Nature Biotechnology · doi:10.1038/s41587-023-02060-8 · Cited by 303 · see citing works

CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma

Choi, B. D., Yu, X., Castaño, A. P., Darr, H., Henderson, D. B., Bouffard, A. A., Larson, R. C., Scarfò, I., Bailey, S. R., Gerhard, G. M., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0806-7 · Cited by 293 · see citing works

Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier

Vafaei, S., Zekiy, A. O., Khanamir, R. A., Zaman, B. A., Ghayourvahdat, A., Azimizonuzi, H., & Zamani, M. (2022) · Cancer Cell International · doi:10.1186/s12935-021-02407-8 · Cited by 278 · see citing works

Probiotic-guided CAR-T cells for solid tumor targeting

Vincent, R. L., Gurbatri, C. R., Li, F., Vardoshvili, A., Coker, C., Im, J., Ballister, E. R., Rouanne, M., Savage, T., de los Santos-Alexis, K., et al. (2023) · Science · doi:10.1126/science.add7034 · Cited by 273 · see citing works

Challenges and new technologies in adoptive cell therapy

Zhang, P., Zhang, G., & Wan, X. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01492-8 · Cited by 271 · see citing works

Engineered cellular immunotherapies in cancer and beyond

Finck, A., Blanchard, T., Roselle, C., Golinelli, G., & June, C. (2022) · Nature Medicine · doi:10.1038/s41591-022-01765-8 · Cited by 240 · see citing works

Genetically engineered T cells for cancer immunotherapy

Li, D., Li, X., Zhou, W.-L., Huang, Y., Liang, X., Jiang, L., Yang, X., Sun, J., Li, Z., Han, W., et al. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0070-9 · Cited by 245 · see citing works

Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment

Liu, G., Rui, W., Zhao, X., & Lin, X. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00655-2 · Cited by 240 · see citing works

CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions

Mardiana, S., & Gill, S. I. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00697 · Cited by 235 · see citing works

Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity

Lai, J., Mardiana, S., House, I. G., Sek, K., Henderson, M. A., Giuffrida, L., Chen, A. X. Y., Todd, K. L., Petley, E. V., Chan, J. D., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0676-7 · Cited by 222 · see citing works

Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies

Wang, H., Kaur, G., Sankin, A. I., Chen, F., Guan, F., & Zang, X. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0746-1 · Cited by 204 · see citing works

Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets

Luo, X., Wu, K., & He, X. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01968-w · Cited by 203 · see citing works

Gene editing for immune cell therapies

Bailey, S. R., & Maus, M. V. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0137-8 · Cited by 202 · see citing works

Arming CAR-T cells with cytokines and more: Innovations in the fourth-generation CAR-T development

Tang, L., Pan, S. D., Wei, X., Xu, X., & Wei, Q. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.09.021 · Cited by 201 · see citing works

Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy

Liu, Z., Zhou, Z., Dang, Q., Xu, H. M., Lv, J., Li, H., & Han, X. (2022) · Theranostics · doi:10.7150/thno.76854 · Cited by 198 · see citing works

Tumor Abnormality-Oriented Nanomedicine Design

Zhou, Q., Xiang, J., Qiu, N., Wang, Y., Piao, Y., Shao, S., Tang, J., Zhou, Z., & Shen, Y. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00062 · Cited by 194 · see citing works

CRISPR Screening of CAR T Cells and Cancer Stem Cells Reveals Critical Dependencies for Cell-Based Therapies

Wang, D., Prager, B. C., Gimple, R. C., Aguilar, B., Alizadeh, D., Tang, H., Lv, D., Starr, R., Brito, A., Wu, Q., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1243 · Cited by 185 · see citing works

Natural killer cells in clinical development as non-engineered, engineered, and combination therapies

Lamers-Kok, N., Panella, D., Georgoudaki, A.-M., Liu, H., Özkazanc, D., Kucerova, L., Duru, A., Spanholtz, J., & Raimo, M. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01382-5 · Cited by 168 · see citing works

CAR T‐cell therapy: Full speed ahead

Sermer, D. J., & Brentjens, R. J. (2019) · Hematological Oncology · doi:10.1002/hon.2591 · Cited by 183 · see citing works

Combination of metabolic intervention and T cell therapy enhances solid tumor immunotherapy

Hao, M., Hou, S., Li, W., Li, K., Xue, L., Hu, Q., Zhu, L., Chen, Y., Sun, H., Ju, C., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz6667 · Cited by 183 · see citing works

Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies

Ruella, M., Korell, F., Porazzi, P., & Maus, M. V. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00807-1 · Cited by 182 · see citing works

TRUCKS, the fourth‐generation CAR T cells: Current developments and clinical translation

Chmielewski, M. M., & Abken, H. (2020) · Advances in Cell and Gene Therapy · doi:10.1002/acg2.84 · Cited by 177 · see citing works

PD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challenges

McGowan, E. M., Lin, Q., Ma, G., Yin, H., Chen, S., & Lin, Y. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109625 · Cited by 174 · see citing works

Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies

Shah, N. N., Maatman, T. C., Hari, P., & Johnson, B. D. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00146 · Cited by 173 · see citing works

CAR T-cell therapy in hematologic malignancies: a voyage in progress.

Holstein, S. A., & Lunning, M. A. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1674 · Cited by 172 · see citing works

Beyond the blood: expanding CAR T cell therapy to solid tumors

Uslu, U., & June, C. H. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02446-2 · Cited by 170 · see citing works

Counteracting CAR T cell dysfunction

Poorebrahim, M., Melief, J., de Coaña, Y. P., Wickström, S. L., Cid-Arregui, Á., & Kiessling, R. W. (2020) · Oncogene · doi:10.1038/s41388-020-01501-x · Cited by 169 · see citing works

Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors

Liu, Y., Liu, G., Wang, J., Zheng, Z., Jia, L., Rui, W., Huang, D., Zhou, Z., Zhou, L., Wu, X., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abb5191 · Cited by 168 · see citing works

Genetic engineering of T cells for immunotherapy

Ellis, G. I., Sheppard, N. C., & Riley, J. L. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00329-9 · Cited by 166 · see citing works

Burst release of encapsulated annexin A5 in tumours boosts cytotoxic T-cell responses by blocking the phagocytosis of apoptotic cells

Li, L., Zou, J., Dai, Y., Fan, W., Niu, G., Yáng, Z., & Chen, X. S. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-0599-5 · Cited by 163 · see citing works

Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed/refractory non-small cell lung cancer patients

Zhang, Y., Zhang, Z., Ding, Y., Fang, Y., Wang, P., Chu, W., Jin, Z., Yang, X., Wang, J., Lou, J., et al. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03613-7 · Cited by 160 · see citing works

Tumor derived UBR5 promotes ovarian cancer growth and metastasis through inducing immunosuppressive macrophages

Song, M. L., Yeku, O., Rafiq, S., Purdon, T. J., Dong, X., Zhu, L., Zhang, T., Wang, H., Yu, Z., Mai, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-20140-0 · Cited by 159 · see citing works

One-step generation of modular CAR-T cells with AAV–Cpf1

Dai, X., Park, J. J.-Y., Du, Y., Kim, H. R., Wang, G., Errami, Y., & Chen, S. (2019) · Nature Methods · doi:10.1038/s41592-019-0329-7 · Cited by 157 · see citing works

Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma

Cao, Y., Lu, W., Sun, R., Jin, X. K., Cheng, L., He, X., Wang, L., Yuan, T., Lyu, C., & Zhao, M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00767 · Cited by 152 · see citing works

Enhanced intratumoural activity of CAR T cells engineered to produce immunomodulators under photothermal control

Miller, I. C., Zamat, A. H., Sun, L.-K., Phuengkham, H., Harris, A. M., Gamboa, L., Yang, J., Murad, J. P., Priceman, S. J., & Kwong, G. A. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00781-2 · Cited by 148 · see citing works

CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1–positive B-Cell Lymphoma

Liu, H., Lei, W., Zhang, C., Yang, C., Wei, J., Guo, Q., Guo, X., Chen, Z., Lu, Y., Young, K. H., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1457 · Cited by 144 · see citing works

The clinical landscape of CAR NK cells

Jørgensen, L. V., Christensen, E. B., Barnkob, M. B., & Barington, T. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00633-8 · Cited by 146 · see citing works

Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy

Stock, S., Schmitt, M. W., & Sellner, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246223 · Cited by 143 · see citing works

Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells

Strohl, W. R., & Naso, M. F. (2019) · Antibodies · doi:10.3390/antib8030041 · Cited by 136 · see citing works

Targeting immune checkpoints in hematological malignancies

Salik, B., Smyth, M. J., & Nakamura, K. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00947-6 · Cited by 136 · see citing works

Reinvigorating exhausted CD8 + cytotoxic T lymphocytes in the tumor microenvironment and current strategies in cancer immunotherapy

Hossain, M. A., Liu, G., Dai, B., Si, Y., Yang, Q., Wazir, J., Birnbaumer, L., & Yang, Y. (2020) · Medicinal Research Reviews · doi:10.1002/med.21727 · Cited by 136 · see citing works

Current trends in sensitizing immune checkpoint inhibitors for cancer treatment

Wei, J., Li, W., Zhang, P., Guo, F., & Liu, M. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02179-5 · Cited by 134 · see citing works

The Tolerogenic Function of Regulatory T Cells in Pregnancy and Cancer

Jørgensen, N., Persson, G., & Hviid, T. V. F. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00911 · Cited by 133 · see citing works

Adoptive CD8+ T cell therapy against cancer:Challenges and opportunities

Jiang, X., Jiang, X., Liu, M., Xing, H., Wang, Z., Huang, L., Mellor, A. L., Wang, W., & Wu, S. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.07.017 · Cited by 129 · see citing works

Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer

Lv, J., Zhao, R., Wu, D., Zheng, D., Wu, Z., Shi, J., Wei, X., Wu, Q., Long, Y., Lin, S., et al. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0704-y · Cited by 128 · see citing works

Cell-based drug delivery systems and their in vivo fate.

Yang, L., Yang, Y., Chen, Y., Xu, Y., & Peng, J. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114394 · Cited by 118 · see citing works

Advancing CAR T cell therapy through the use of multidimensional omics data

Yang, J., Chen, Y., Jing, Y., Green, M. R., & Han, L. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00729-2 · Cited by 128 · see citing works

Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T

Liu, Q., Li, J., Zheng, H., Yang, S., Hua, Y., Huang, N., Kleeff, J. H., Liao, Q., & Wu, W. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01735-9 · Cited by 126 · see citing works

Overcoming Heterogeneity of Antigen Expression for Effective CAR T Cell Targeting of Cancers

Kailayangiri, S., Altvater, B., Wiebel, M., Jamitzky, S., & Rössig, C. (2020) · Cancers · doi:10.3390/cancers12051075 · Cited by 124 · see citing works

Born to survive: how cancer cells resist CAR T cell therapy

Lemoine, J., Ruella, M., & Houot, R. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01209-9 · Cited by 124 · see citing works

Antibody and antibody fragments for cancer immunotherapy

Chen, W., Yang, Y., & Jiang, X. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.08.021 · Cited by 120 · see citing works

Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56

Zou, F., Lu, L., Liu, J., Xia, B., Zhang, W., Hu, Q., Liu, W., Zhang, Y., Lin, Y., Jing, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11893-4 · Cited by 118 · see citing works

Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment

Pearson, J. R. D., Cuzzubbo, S., McArthur, S., Durrant, L. G., Adhikaree, J., Tinsley, C. J., Pockley, A. G., & McArdle, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.582106 · Cited by 118 · see citing works

Improving CAR T-Cell Persistence

Pietrobon, V., Todd, L. A., Goswami, A., Stefanson, O., Yang, Z., & Marincola, F. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910828 · Cited by 118 · see citing works

Target delivery of a PD-1-TREM2 scFv by CAR-T cells enhances anti-tumor efficacy in colorectal cancer

Chen, J., Zhu, T., Jiang, G., Zeng, Q., Li, Z., & Huang, X. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01830-x · Cited by 117 · see citing works

In situ generation of micrometer-sized tumor cell-derived vesicles as autologous cancer vaccines for boosting systemic immune responses

Guo, Y., Wang, S.-Z., Zhang, X., Jia, H., Zhu, Y., Zhang, X., Gao, G., Jiang, Y., Li, C., Chen, X., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33831-7 · Cited by 115 · see citing works

Design and Characterization of an “All-in-One” Lentiviral Vector System Combining Constitutive Anti-GD2 CAR Expression and Inducible Cytokines

Zimmermann, K., Kuehle, J., Dragon, A. C., Galla, M., Kloth, C., Rudek, L. S., Sandalcioglu, I. E., Neyazi, B., Moritz, T., Meyer, J., et al. (2020) · Cancers · doi:10.3390/cancers12020375 · Cited by 111 · see citing works

DNA scaffolds enable efficient and tunable functionalization of biomaterials for immune cell modulation

Huang, X., Williams, J. Z., Chang, R., Li, Z., Burnett, C. E., Hernández-López, R. A., Setiady, I., Gai, E., Patterson, D. M., Yu, W., et al. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-00813-z · Cited by 111 · see citing works

Immunotherapy for Glioblastoma: Adoptive T-cell Strategies

Choi, B. D., Maus, M. V., June, C. H., & Sampson, J. H. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1625 · Cited by 109 · see citing works

Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy

Xia, X., Yang, Z., Lu, Q., Liu, Z., Wang, L., Du, J., Li, Y., Yang, D.-H., & Wu, S.-J. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02079-8 · Cited by 110 · see citing works

A chimeric antigen receptor with antigen-independent OX40 signaling mediates potent antitumor activity

Zhang, H., Li, F., Cao, J., Wang, X., Cheng, H., Qi, K., Wang, G., Xu, K., Zheng, J., Fu, Y., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.aba7308 · Cited by 108 · see citing works

Ionizable Lipid Nanoparticles with Integrated Immune Checkpoint Inhibition for mRNA CAR T Cell Engineering

Hamilton, A. G., Swingle, K. L., Joseph, R. A., Mai, D., Gong, N., Billingsley, M. M., Alameh, M., Weissman, D., Sheppard, N. C., June, C. H., et al. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202301515 · Cited by 108 · see citing works

T Cells in Colorectal Cancer: Unravelling the Function of Different T Cell Subsets in the Tumor Microenvironment

Zheng, Z., Wieder, T., Mauerer, B., Schäfer, L., Kesselring, R., & Braumüller, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411673 · Cited by 105 · see citing works

CAR-T cells in solid tumors: Challenges and breakthroughs

Escobar, G., Berger, T. R., & Maus, M. V. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102353 · Cited by 104 · see citing works

Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies

Zhang, Z., Wang, T., Wang, X.-F., Zhang, Y., Song, S., & Ma, C. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.106036 · Cited by 103 · see citing works

CAR‑T cell therapy: A breakthrough in traditional cancer treatment strategies (Review)

Sun, D., Shi, X., Li, S., Wang, X., Xiao, Y., & Wan, M. (2024) · Molecular Medicine Reports · doi:10.3892/mmr.2024.13171 · Cited by 103 · see citing works

EZH1 repression generates mature iPSC-derived CAR T cells with enhanced antitumor activity

Jing, R., Scarfò, I., Najia, M. A. T., da Rocha, E. L., Han, A., Sanborn, M., Bingham, T., Kubaczka, C., Jha, D. K., Falchetti, M., et al. (2022) · Cell stem cell · doi:10.1016/j.stem.2022.06.014 · Cited by 96 · see citing works

Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies

Tao, Z., Chyra, Z., Kotulová, J., Celichowski, P., Mihályová, J., Charvátová, S., & Hájek, R. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01193-6 · Cited by 96 · see citing works

Engineered CAR-T cells targeting TAG-72 and CD47 in ovarian cancer

Shu, R., Evtimov, V. J., Hammett, M. V., Nguyen, N.-Y. N., Zhuang, J., Hudson, P. J., Howard, M., Pupovac, A., Trounson, A. O., & Boyd, R. L. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.01.002 · Cited by 95 · see citing works

Abstract 2568: CAR T cells secreting an immune checkpoint blockade scFv have enhanced anti-tumor efficacy

Rafiq, S., Yeku, O., Jackson, H. J., Purdon, T. J., van Leeuwen, D. G., Yan, S., Wang, P., Xiang, J., Liu, C., Seshan, V., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-2568

Enhancing CAR T Cell Anti-Tumor Efficacy through Secreted Single Chain Variable Fragment (scFv) Immune Checkpoint Blockade

Rafiq, S., Jackson, H. J., Yeku, O., Purdon, T. J., van Leeuwen, D. G., Curran, K. J., Ahmed, R. N., Cullen, G. D., Yan, S., Wang, P., et al. (2017) · Blood · doi:10.1182/blood.v130.suppl_1.842.842 · Cited by 6 · see citing works

Augmenting the Effectiveness of CAR-T Cells by Enhanced Self-Delivery of PD-1-Neutralizing scFv

Yü, P., Li, F., Nan, S., Zhang, D., Shi, X., Shan, J., & Zhang, Y. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00803 · Cited by 51 · see citing works

PD-1–Blocking scFV–Secreting CAR T Cells Exhibit Antitumor Efficacy

(2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-rw2018-143

Improved survival of chimeric antigen receptor‐engineered T ( CAR ‐T) and tumor‐specific T cells caused by anti‐programmed cell death protein 1 single‐chain variable fragment‐producing CAR ‐T cells

Nakajima, M., Sakoda, Y., Adachi, K., Nagano, H., & Tamada, K. (2019) · Cancer Science · doi:10.1111/cas.14169 · Cited by 53 · see citing works